Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolism and Pharmacokinetics of [14C]-Cilobradine in Healthy Volunteers
NCT02264028Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2004
- Primary completion
- Apr 2004
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of cilobradine in cardiovascular diseases (CVD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum measured concentration of the analytes in plasma up to 96 hours, Area under the concentration-time curve of the analytes in plasma up to 96 hours and 21 more. Started Mar 2004; status: completed.
02
Drugs
cilobradine
03
Conditions
cardiovascular diseases (CVD)
Beyond the preview
Go deeper on NCT02264028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02264028.